BAYOU: A phase II, randomized, multicenter, double-blind, study of durvalumab (D) in combination with olaparib (O) for the first-line treatment of platinum-ineligible patients with unresectable, stage IV urothelial carcinoma (UC).

被引：18

作者：

Rosenberg, Jonathan E.

Park, Se Hoon

Dao, Tu V.

Castellano, Daniel E.

Li, Jian-Ri

Mukherjee, Som

Howells, Kathryn

Dry, Hannah

Lanasa, Mark C.

Stewart, Ross

Bajorin, Dean F.

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Sungkyunkwan Univ, Samsung Med Ctr, Seoul, South Korea

[3] Natl Canc Hosp, Hanoi, Vietnam

[4] Hanoi Med Univ, Hanoi, Vietnam

[5] Hosp Univ 12 Octubre, Madrid, Spain

[6] HungKuang Univ, Taichung Vet Gen Hosp, Taichung, Taiwan

[7] Hamilton Hlth Sci, Juravinski Canc Ctr, Hamilton, ON, Canada

[8] McMaster Univ, Hamilton, ON, Canada

[9] AstraZeneca, Cambridge, England

[10] AstraZeneca, Gaithersburg, MD USA

来源：

关键词：

D O I：

10.1200/JCO.2022.40.6_suppl.437

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

437

引用

页数：3